登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C22H30N6O4S ·C6H8O7
化学文摘社编号:
分子量:
666.70
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
sildenafil
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCc1nn(C)c2C(=O)NC(=Nc12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4
InChI
1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
InChI key
DEIYFTQMQPDXOT-UHFFFAOYSA-N
Gene Information
human ... PDE5A(8654)
General description
本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。
Application
西地那非柠檬酸盐EP参考标准品的预期用途是欧洲药典规定的实验室测试。
Biochem/physiol Actions
西地那非是cGMP特异性5型磷酸二酯酶(PDE5)的一种有效选择性抑制剂。西地那非可用于治疗勃起功能障碍和肺动脉高压。
西地那非是cGMP特异性5型磷酸二酯酶(PDE5)的一种有效选择性抑制剂。西地那非可用于治疗勃起功能障碍和肺动脉高压。NO可激活鸟苷酸环化酶,从而导致cGMP水平增加并产生平滑肌松弛。西地那非可通过抑制负责cGMP降解的PDE5来增强NO的作用。
Packaging
本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录。
Other Notes
可能适用相应的销售限制。
Still not finding the right product?
Explore all of our products under 西地那非
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lisa Nivison-Smith et al.
Experimental eye research, 128, 43-56 (2014-09-23)
Sildenafil, the active ingredient in Viagra, has been reported to cause transient visual disturbance from inhibition of phosphodiesterase 6 (PDE6), a key enzyme in the visual phototransduction pathway. This study investigated the effects of sildenafil on the rd1(+/-) mouse, a
Jing Peng et al.
Urology, 84(6), 1389-1394 (2014-10-13)
To evaluate the results of nocturnal penile erection test and response to daily sildenafil in patients with erectile dysfunction (ED) due to pelvic fracture urethral disruption. From January 2010 to January 2012, we included 38 patients with ED due to
U Ozturk et al.
Irish journal of medical science, 183(3), 449-453 (2013-11-06)
It has been shown on experimental rat models that type 5-phosphodiesterase isoenzyme (PDE5) inhibitors have anti-fibrotic effects for Peyronie's disease (PD); however, this issue has not been addressed clinically. The aim of this study was to document the effects of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0001578 | 04061837584930 |
